Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease

Herrmann, Nathan; Gauthier, Serge
December 2008
CMAJ: Canadian Medical Association Journal;12/2/2008, Vol. 179 Issue 12, p1279
Academic Journal
Background: The management of severe Alzheimer disease often presents difficult choices for clinicians and families. The disease is characterized by a need for full-time care and assistance with basic activities of daily living. We outline an evidence-based approach for these choices based on recommendations from the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Methods: We developed evidence-based guidelines using systematic literature searches, with specific criteria for the selection and quality assessment of articles, and a clear and transparent decision-making process. We selected articles published from January 1996 to December 2005 that dealt with the management of severe Alzheimer disease. Subsequent to the conference, we searched for additional articles published from January 2006 to March 2008 using the same search terms. We graded the strength of the evidence using the criteria of the Canadian Task Force on Preventive Health Care. Results: We identified 940 articles, of which 838 were selected for further study. Thirty-four articles were judged to be of at least good or fair quality and were used to generate 17 recommendations. Assessment of severe Alzheimer disease should include the measurement of cognitive function and the assessment of behaviour, function, medical status, nutrition, safety and caregiver status. Management could include treatment with a cholinesterase inhibitor or memantine, or both. Treatment of neuropsychiatric symptoms begins with nonpharmacologic approaches to addressing behavioural problems. Severe agitation, aggression and psychosis, which are potentially dangerous to the patient, the caregiver and others in the environment, can be treated with atypical antipsychotics, with consideration of their increased risk of cerebrovascular events and death. All pharmacologic approaches require careful monitoring and periodic reassessment to determine whether continued treatment is necessary. Caregiver support and use of community resources are essential.


Related Articles

  • Updating the Nation's Roadmap to Treat Alzheimer's Disease. MATHENY, Helen // State Journal (WV);8/30/2013, Vol. 29 Issue 34, p37 

    The article argues against the increase of medical care costs for patients with Alzheimer's disease in the U.S.

  • FAST STATS.  // Healthcare Purchasing News;Nov2010, Vol. 34 Issue 11, p6 

    The article presents statistics on the health care industry including statistics on hospitals' use of evidence-based treatments, the success rates of hospital treatments for pneumonia and hospitals' compliance with providing fibrinolytic therapy to heart attack patients.

  • CHOLINESTERASE INHIBITORS AND MEMANTINE: BEST PRACTICES. Doody, Rachelle S. // Primary Psychiatry;Oct2008 Expert Review Supplement, Vol. 15 Issue Suppl. 6, p34 

    The article focuses on evidence-based best practices guidelines in the application of cholinesterase inhibitors and memantine for the treatment of mild, moderate and severe Alzheimer's disease (AD). It offers information on the American Academy of Neurology Management of Dementia Guidelines....

  • Guidelines for Managing Alzheimer's Disease: Part I. Assessment. Cummings, Jeffrey L.; Frank, Janet C.; Cherry, Debra; Kohatsu, Neal D.; Kemp, Bryan; Hewett, Linda; Mittman, Brian // American Family Physician;6/1/2002, Vol. 65 Issue 11, p2263 

    Part I. Offers practical guidance and tools to help family physicians provide a comprehensive management program for patients with Alzheimer's disease. Information on Alzheimer's disease; Areas which require assessment and periodic reassessment in the patient with Alzheimer's disease; Details...

  • Pharmacological treatment of neuropsychiatrie symptoms in Alzheimer's disease: a systematic review and meta-analysis. Jun Wang; Jin-Tai Yu; Hui-Fu Wang; Xiang-Fei Meng; Chong Wang; Chen-Chen Tan; Lan Tan // Journal of Neurology, Neurosurgery & Psychiatry;Jan2015, Vol. 86 Issue 1, p101 

    Background A wide variety of pharmacological agents are used in the management of neuropsychiatric symptoms, which are common in Alzheimer's disease (AD), but results from randomised controlled trials (RCTs) on the efficacy and safety of these agents are conflicting. Objectives To quantify the...

  • Fear not the heat. Godlee, Fiona // BMJ: British Medical Journal (International Edition);11/25/2006, Vol. 333 Issue 7578, p1078 

    The article focuses on the effect a legal challenge from the drug industry in the United Kingdom, concerning the government's proposed attempt to restrict drug treatments for Alzheimer's disease, will have on the government's main medical rationing body, the National Institute for Health and...

  • Alzheimer's care with a human touch. POIROT, CAROLYN // Fort Worth Business Press;8/31/2015, Vol. 27 Issue 29, p20 

    The article mentions that the James L. West Alzheimer's Center in Fort Worth, Texas is training its staff in a form of therapy protocol called "Humanitude," for care of Alzheimer's patients. Topics discussed include development of Humanitude care methods for preventing injuries to caregivers;...

  • Draft of co-occurring report has evidence-based focus.  // Behavioral Health Accreditation & Accountability Alert;Aug2002, Vol. 7 Issue 8, p4 

    Provides information on a draft report on evidence-based treatments for co-occurring mental health and substance use disorders to be submitted by the U.S. Substance Abuse and Mental Health Services Administration to the U.S. Congress in fall 2002. Information on a plan outlined in the draft...

  • Confronting the hierarchy of evidence. Bower, Pete // Healthcare Counselling & Psychotherapy Journal;Oct2007, Vol. 7 Issue 4, p16 

    The article focuses on the medical model in context of research, as studied by the author. He says that the term "medical model" is associated with a philosophical assumption that there is a physical and biological basis to health and disease. He informs that evidence-based medicine was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics